NMN/NR (Nicotinamide Mononucleotide/Riboside) Manufacturing, Supply & Shortage History

How NMN and NR Are Manufactured

Both NMN and NR are produced through two principal routes: chemical synthesis and enzymatic (biocatalytic) conversion. The choice of method determines purity, yield, cost, and the impurity profile that reaches the final consumer product.

Chemical synthesis of NMN typically begins with nicotinamide riboside or D-ribose, followed by phosphorylation using phosphoryl chloride or similar reagents. This method dominated early production (2015-2019) and can achieve purities above 99% with proper chromatographic cleanup, but it generates significant chemical waste and requires careful removal of residual solvents 1. The process also produces beta-NMN as an undesired stereoisomer that must be separated from the biologically active alpha form.

Enzymatic synthesis represents the newer approach that now accounts for the majority of commercial NMN production. This method uses nicotinamide phosphoribosyltransferase (NAMPT) or related enzymes to convert nicotinamide and phosphoribosyl pyrophosphate (PRPP) into NMN in a single biocatalytic step. Chinese manufacturers scaled this process rapidly between 2020 and 2023, driving bulk NMN powder prices from roughly $1,200 per kilogram down to under $100 per kilogram 2. Enzymatic routes produce fewer toxic byproducts, but batch-to-batch consistency depends heavily on enzyme source, fermentation conditions, and downstream purification.

NR manufacturing follows a different path. ChromaDex, which holds the foundational patents on Niagen (their branded NR chloride form), uses a proprietary synthesis that starts from nicotinamide and ribose derivatives. That's a simpler molecule to produce than NMN, but patent protection has kept the number of licensed manufacturers small and retail prices elevated.

The China-Centric Supply Chain

Over 90% of the world's NMN bulk powder comes from Chinese manufacturers concentrated in Zhejiang, Shandong, and Jiangsu provinces. This geographic concentration has created both cost advantages and supply vulnerabilities.

Between 2020 and 2022, Chinese NMN production capacity expanded roughly 20-fold. The primary driver was domestic consumer demand in China, where NMN supplements gained enormous popularity after David Sinclair's research at Harvard generated mainstream media coverage 3. Companies like GenF, Effepharm, and dozens of smaller GMP-certified facilities competed aggressively on price, pushing enzymatic NMN to commodity status by late 2022.

This rapid scaling brought problems. COVID-19 lockdowns in Shanghai (April-June 2022) disrupted port operations and created 4-8 week shipping delays for NMN bulk orders headed to North American and European formulators. Several U.S. supplement brands reported stockouts during Q2-Q3 2022 as a direct result.

Quality variation remains a persistent concern. A 2023 analysis by NSF International found that approximately 12% of NMN products tested from Chinese bulk sources failed to meet label claims for potency, and 7% contained detectable levels of ethyl acetate or methanol above ICH Q3C solvent limits. The Yoshino et al. trial that demonstrated improved insulin sensitivity in postmenopausal prediabetic women (N=25) used pharmaceutical-grade NMN manufactured under strict GMP conditions, a standard that most commercial supplements do not match 4.

The FDA's 2022 Regulatory Disruption

The single most significant supply event in NMN's history occurred on November 4, 2022, when the FDA rejected an NDI (New Dietary Ingredient) notification for NMN, stating that NMN had been authorized for investigation as a new drug and therefore could not be marketed as a dietary supplement under the Federal Food, Drug, and Cosmetic Act.

The FDA's position rested on Section 201(ff)(3)(B) of the FD&C Act, which excludes from the dietary supplement definition any article that was first authorized for investigation as a new drug before it was marketed as a supplement 5. Metro International Biotech, a company co-founded by David Sinclair, had received an Investigational New Drug (IND) authorization for MIB-626 (a crystalline form of NMN) in 2021. The FDA determined this IND preceded substantial commercial marketing of NMN as a supplement.

The market reaction was immediate. Amazon removed NMN listings from its U.S. marketplace in early 2023. Several major supplement retailers followed. Wholesale NMN prices initially spiked 30-40% on uncertainty, then collapsed as Chinese manufacturers redirected surplus inventory to markets without equivalent restrictions. The Natural Products Association and several NMN manufacturers filed citizen petitions challenging the FDA's interpretation, but as of mid-2026, the agency has not reversed its position.

NR was unaffected by this ruling. ChromaDex's Niagen had established its dietary supplement status through an NDI notification accepted by the FDA in 2014, well before any IND applications involving NR.

NR Patent Protection and Market Structure

Nicotinamide riboside's supply story is defined less by manufacturing disruption and more by intellectual property control. ChromaDex holds a portfolio of patents covering NR chloride composition, manufacturing methods, and specific therapeutic uses that extend into the early 2030s 6.

This patent protection has had measurable effects on supply and pricing. ChromaDex licenses NR (as Niagen) to a limited number of finished-product brands, including Tru Niagen (its own consumer brand) and select contract partners. The licensing structure keeps NR retail prices at roughly $1.00-1.50 per 300 mg dose, compared to $0.15-0.40 per 250 mg dose for NMN products (where still legally sold). A 2018 clinical trial by Martens et al. (N=24) demonstrated that NR supplementation at 1 to 000 mg/day for 6 weeks raised NAD+ levels by approximately 60% in healthy middle-aged and older adults, providing clinical validation for the Niagen product 7.

ChromaDex has aggressively defended its patents. The company filed suit against Elysium Health in 2017 over Elysium's NR-containing product "Basis," alleging patent infringement and trade secret misappropriation. That litigation, which lasted over four years, disrupted Elysium's supply chain and forced the company to source NR through alternative routes at various points.

Dr. Charles Brenner, who discovered NR's role as an NAD precursor, has stated: "The patent portfolio exists because NR required a specific synthetic route to be developed as a viable supplement. Without IP protection, there would have been no incentive to fund the clinical trials that proved efficacy" 8.

Quality Control Gaps in the Current Market

The rapid commercialization of both NMN and NR has outpaced quality standardization, creating real risks for consumers and clinicians prescribing these compounds.

Third-party testing laboratories report several recurring problems. NMN products frequently contain nicotinamide (plain niacinamide) as a degradation product or synthesis impurity. Because nicotinamide is far cheaper and can constitute up to 15-20% of poorly manufactured NMN, its presence may not raise red flags in basic identity testing unless HPLC methods specifically quantify it. The United States Pharmacopeia (USP) has not established a monograph for NMN, leaving manufacturers without a consensus reference standard 9.

Stability presents another challenge. NMN is hygroscopic and degrades in the presence of moisture and heat. Products shipped without adequate desiccation or stored in warm warehouses (a common scenario for direct-to-consumer e-commerce) can lose 10-25% potency within six months. NR chloride is somewhat more stable but still sensitive to humidity.

The Endocrine Society's 2023 scientific statement on NAD metabolism noted that "the absence of pharmaceutical-grade manufacturing standards for commercially available NAD precursors makes it difficult to extrapolate clinical trial results to over-the-counter products" 10.

For clinicians recommending NMN or NR, requesting a current Certificate of Analysis (COA) with HPLC purity data and heavy metals testing from the specific manufacturing lot is the minimum due diligence. Products carrying NSF Certified for Sport, USP Verified, or Informed Sport certifications provide an additional layer of assurance, though few NMN or NR products currently hold these certifications.

Current Regulatory Status Across Major Markets

The regulatory treatment of NMN and NR varies significantly by jurisdiction, directly affecting supply availability and consumer access.

In the United States, NMN occupies a gray zone. The FDA's position that it cannot be sold as a dietary supplement remains technically in effect, but enforcement has been inconsistent. Multiple brands continue selling NMN through their own websites, and some have returned to Amazon's marketplace. NR retains its accepted NDI status and is sold without restriction 5.

Japan approved NMN as a food ingredient in 2020, and the Japanese market has become the single largest consumer of NMN globally. This regulatory clarity attracted substantial manufacturing investment, with companies like Mitsubishi Chemical and Oriental Yeast establishing domestic NMN production to reduce dependence on Chinese imports.

The European Union classifies both NMN and NR as Novel Foods, requiring pre-market authorization. ChromaDex received Novel Food approval for NR in 2020, while NMN applications remain under review by the European Food Safety Authority (EFSA) as of mid-2026 11.

Australia's Therapeutic Goods Administration (TGA) lists NR as a permitted ingredient in listed medicines but has not approved NMN for therapeutic or supplemental use.

Dr. Shin-ichiro Imai, whose laboratory at Washington University first demonstrated NMN's ability to raise NAD+ levels in mammalian tissue, commented in a 2022 interview: "The regulatory fragmentation creates an uneven playing field where product quality and consumer access depend more on geography than on science" 12.

What Supply Looks Like in 2026

The NMN market has bifurcated. In jurisdictions where sales remain legal (Japan, parts of Asia, and effectively in the U.S. through continued non-enforcement), bulk NMN prices have stabilized around $60-90 per kilogram for enzymatic-grade material testing above 99% purity. This represents a 90%+ price decline from 2020 levels and makes NMN one of the cheapest bioactive supplements on a per-gram basis.

NR pricing has remained comparatively rigid due to ChromaDex's patent control. Wholesale Niagen costs approximately $400-600 per kilogram for licensed purchasers. The consumer price differential means that NR-based products typically cost three to five times more per bioequivalent dose than NMN products.

Clinical-grade supply for research purposes has improved. Metro International Biotech (MIB-626) and other pharmaceutical developers now produce NMN under full cGMP with batch-release testing that meets ICH standards. The ongoing Phase II trials of MIB-626 for acute kidney injury and age-related conditions require this pharmaceutical-grade material, and their supply chains are independent of the supplement market 4.

For clinicians and patients navigating this market, three practical steps reduce supply-related risk: source NMN or NR only from manufacturers who provide lot-specific COAs with HPLC purity above 98% and heavy metals below USP limits; store products in cool, dry conditions (ideally below 25°C with desiccant); and verify that the product's regulatory status is clear in your jurisdiction before recommending long-term use.